Empagliflozin
Empagliflozin has been studied in 495 papers since 2016: 94 trials and 117 observational studies in people, 105 in animals, 23 in cells, 114 reviews; 325 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.
InterventionSGLT2 inhibitorsApproved 2014
495 papers study it26 more mention it732 findingsUpdated
Part of Bryan Johnson's Blueprint
123 new papers in 30 daysSee all 509 papers on empagliflozin
At a glance
Empagliflozin lowers hospitalization and cardiorenal event risks in human trials, but frailty results differ between trials. Independent labs report reduced cellular senescence in cells, with an opposing result in mice. Some human papers declare ties to its developers, Boehringer Ingelheim and Eli Lilly.
732 findings in 276 papers from 2016 to 2026, 102 of them since April 2026
Independent labs found the same change in cells, mice and people. 172 independent labs in 43 countries; 298 trials, 80 about aging, 70 with no results posted.
“sotagliflozin (OR 0.50; 95% CI: 0.40-0.63;p-score=0.98), empagliflozin (OR 0.69; 95% CI 0.62-0.76; p-score=0.88), and metformin (OR 0.79; 95% CI 0.35-1.75; p-score=0.63) had lowest odds of mortality”
41 of its findings point the other way.
- 172 independent labs in 43 countries
- 41 findings against
- 298 trials, 80 about aging, 70 with no results posted
- Funders: Boehringer Ingelheim and others
- 143 of 687 findings with company ties
- 92 of 298 trials sponsored by its developers
- Human trial94
- Humans115
- Animals97
- Cells22
- In silico15
Studies in people
See all 71 studies of empagliflozin in people71 studies gave empagliflozin to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases hospitalization for heart failure or cardiovascular deathHR 0.91 with no DD criteria, 0.64 with 1, and 0.49 with ≥2; treatment trend P=.0014 | Randomized trial | 5,988 peopleHeart failure with preserved ejection fraction; increasing baseline diastolic dysfunction criteria | European journal of heart failure, Nov 5, 2026 |
down: Decreases TNF-alpha down: Decreases mitochondrial reactive oxygen species production | Trial90 days | 11 peopleINOCA with coronary microvascular dysfunction | AHA Scientific Sessions 2026 abstract, Nov 2, 2026 |
down: Lowers the risk of postoperative atrial fibrillation12.9% versus 26.8%; OR 0.40, 95% CI 0.25–0.65 no change: Has no effect on life-threatening arrhythmias3 versus 7 patients; P = 0.33 no change: Has no effect on acute kidney injury | Randomized trialAt least 3 days before surgery until discharge (maximum 30 days) | 467 peopleBoth61.3 ± 9.0 yearsMidlife adults; Non-diabetic patients undergoing elective isolated coronary artery bypass grafting | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases PRO-C3Adjusted ratio of change 0.90, 95% CI 0.85–0.95; 10% relative reduction no change: Has no effect on PRO-C6Adjusted ratio of change 0.99, 95% CI 0.95–1.03; P=0.54 | Review of trials12 or 24 weeks | 380 people pooledPatient cohorts | ESC Congress 2026 abstract, Oct 26, 2026 |
up: Increases ≥5% body weight reductionOR 1.88, 95% CI 1.18–2.99 down: Decreases systolic blood pressure | Randomized trial180 days | 800 peopleChronic kidney disease and type 2 diabetes | ESC Congress 2026 abstract, Oct 26, 2026 |
What did studies of empagliflozin find?
451Studies of empagliflozin measured 451 outcomes; the most studied are inflammation (17 studies), cellular senescence (13) and oxidative stress and ROS signaling (12).
Inflammation
downin mice9downin rats5downin human cells1downin mouse cells1+1
17 studies
Inflammation
downin mice9downin rats5downin human cells1downin mouse cells1+1
Empagliflozin decreases inflammation in mice (diabetic cardiomyopathy induced by high-fat diet and streptozotocin).
“EX, EMPA, EX combined with EMPA intervention significantly attenuated inflammation cell infiltration”
Animalsdiabetic cardiomyopathy induced by high-fat diet and streptozotocinheart8 weeksmalesn = 12
Frontiers in endocrinology
Empagliflozin decreases inflammation in mouse cells (IL-1β-stimulated chondrocytes).
“EMP promoted anabolism, inhibited the inflammatory response and catabolism in IL-1β stimulated chondrocytes.”
CellsIL-1β-stimulated chondrocyteschondrocyte
Biomedicines
Empagliflozin decreases inflammation in mice (isoprenaline-induced HFpEF model).
“Empagliflozin lowered resting flow, normalized CFR, reduced endothelial permeability and inflammatory signaling”
Animalsisoprenaline-induced HFpEF modeldays 7–21
International journal of cardiology
Empagliflozin decreases inflammation in rats (post-cardiac arrest).
“both empagliflozin and BHB treatment attenuated microglial activation”
Animalspost-cardiac arrestmales
Journal of the American Heart Association
Empagliflozin decreases inflammation in mouse models of HF induced by transverse aortic constriction.
“Empagliflozin decreased cardiac C-C chemokine receptor type 2-positive macrophages, suggesting attenuated inflammation.”
Animalsin mouse models of HF induced by transverse aortic constriction2 weeks
Journal of the American Heart Association
Empagliflozin decreases inflammation in rats (combined with trandolapril in Ren-2 transgenic rats).
“attenuated inflammation (leptin, MCP-1, TNFα) and steatotic gene markers”
Animalscombined with trandolapril in Ren-2 transgenic ratsmales
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Empagliflozin decreases inflammation in mice (mouse models of Parkinson’s disease).
“empagliflozin has demonstrated the ability to improve motor functions, lower neuroinflammation, and promote neuroplasticity in mouse models of Parkinson’s disease.”
Reviewmouse models of Parkinson’s disease
POTENTIAL EFFECTS OF SGLT-2 INHIBITORS ON PARKINSON DISEASE
TOGÜ Sağlık Bilimleri Dergisi
Empagliflozin decreases inflammation in rats (doxorubicin-induced nephrotoxicity).
“Collectively, antioxidant, anti-inflammatory, and antiapoptotic influences contributed to the preservative potential of EMPA against DOX-induced kidney toxicity.”
Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales
The Journal of pharmacology and experimental therapeutics
Empagliflozin decreases inflammation in O. cuniculus (carrageenan-induced ocular inflammation).
“The silicon dioxide-loaded film (EMA3) showed significantly lowered intraocular pressure and promising ocular anti-inflammation”
Animalscarrageenan-induced ocular inflammationsilicon dioxide-loaded HPMC ocular film (EMA3)eye
Hypotension and antiphlogistic potential of empagliflozin ocular film: swelling and release kinetics
ADMET & DMPK
Empagliflozin decreases inflammation in human cells (high-glucose exposure (33 mM) in AC16 cells).
“Empagliflozin reversed high-glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic, and aging signatures.”
Cellshigh-glucose exposure (33 mM) in AC16 cellscardiomyocyte2 and 7 days
European journal of heart failure
All 17Fewer
Cellular senescence
downin mice5downin human cells2downin mouse cells2downin pig cells2+3
13 studies
Cellular senescence
downin mice5downin human cells2downin mouse cells2downin pig cells2+3
Empagliflozin decreases cellular senescence in mouse cells.
“EMP enhanced autophagic activity and attenuated senescent phenotype in vitro.”
Cellschondrocyte
Biomedicines
Empagliflozin increases cellular senescence in distal tubular cells, with CDKN2A and CDKN1A co-upregulation.
“Twenty-four weeks post-cessation, these cells exhibited senescence with co-upregulation of CDKN2A and CDKN1A, EMT progression, and renal interstitial fibrosis.”
Animalsin distal tubular cells, with CDKN2A and CDKN1A co-upregulationdistal tubular cell24 weeks post-cessation
Biochemical pharmacology
Empagliflozin decreases cellular senescence in mice (natural aging, male C57 mice, versus vehicle).
“in Old-EMPA group, the expression of P16 and SA-β-gal were downregulated compared to Old-vehicle group”
Animalsnatural aging, male C57 mice, versus vehiclekidneymales
Empagliflozin slows down natural kidney senescence via Six1/Wnt4/NF-κB pathway
Biogerontology
Empagliflozin decreases cellular senescence in HFpEF mice fed high-fat diet with L-NAME.
“EMPA treatment suppressed the increase in the levels of aging markers (p16 and p21) in HFpEF hearts.”
Animalsin HFpEF mice fed high-fat diet with L-NAMEheart4 weeks
Cardiovascular diabetology
Empagliflozin decreases cellular senescence in mice with peritoneal dialysis.
“p53, p21, and p16 increased in mice with PD compared with those in the control group; however, these changes were decreased by empagliflozin.”
Animalsin mice with peritoneal dialysisparietal peritoneummales
American journal of physiology. Renal physiology
Empagliflozin decreases cellular senescence in human cells (glucose-treated HPMCs).
“Reactive oxygen species production, DNA damage, senescence, and EMT markers were increased by glucose treatment; however, cotreatment with glucose and empagliflozin attenuated these changes.”
Cellsglucose-treated HPMCs
American journal of physiology. Renal physiology
Empagliflozin decreases cellular senescence in naturally aged mice.
“downregulated the hepatic protein expression of P21, P16, α-SMA, and COL1A1”
Animalsin naturally aged miceliver
Empagliflozin rescues lifespan and liver senescence in naturally aged mice
GeroScience
Empagliflozin decreases cellular senescence in diabetic nephropathy mice, bioinformatic analysis.
“This finding indicated that empagliflozin may inhibit the progression of diabetic nephropathy by inhibiting inflammation, apoptosis, and senescence.”
Animalsin diabetic nephropathy mice, bioinformatic analysis
Archivos espanoles de urologia
Empagliflozin decreases cellular senescence in human cells (ponatinib-induced endothelial toxicity) (4 ± 1 versus 9 ± 4 β-Gal+ cells/field).
“EMPA and DAPA also reversed the effects of PON on cell senescence”
Cellsponatinib-induced endothelial toxicityhuman aortic endothelial cells500 nmol/L
Vascular pharmacology
Empagliflozin decreases cellular senescence in hHTG rats fed standard diet.
“along with reduction of markers of inflammation, oxidative stress and cell senescence”
Animalsin hHTG rats fed standard dietliver, adipose tissue and kidneysix weeksmales
International journal of molecular sciences
All 14Fewer
Oxidative stress and ROS signaling
downin rats6downin mice3downin humans1downin pig cells1+1
12 studies
Oxidative stress and ROS signaling
downin rats6downin mice3downin humans1downin pig cells1+1
Empagliflozin decreases oxidative stress and ROS signaling in humans (Lower TOS and OSI and higher TAS at both follow-up visits; all p < 0.001).
“The exploratory mixed-effects models showed lower TOS and OSI and higher TAS in the study group at both follow-up visits (all p < 0.001).”
Human trialHeart failure and predominantly obstructive sleep apnea; CPAP initiated in both groups after month 310 mg daily3 and 6 monthsn = 70
Empagliflozin linked to milder sleep apnea in heart failure
Antioxidants (Basel, Switzerland)
Empagliflozin decreases oxidative stress and ROS signaling.
“including modulation of AMPK signaling, attenuation of oxidative stress, and suppression of inflammatory activation.”
ReviewEvidence predominantly from experimental cardiovascular or metabolic disease models, rather than physiological aging studies
Frontiers in pharmacology
Empagliflozin decreases oxidative stress and ROS signaling in mice (ATO-treated).
“EMPA treatment effectively inhibits ATO-induced oxidative stress and reduces apoptosis.”
AnimalsATO-treated
Journal of toxicology
Empagliflozin decreases oxidative stress and ROS signaling in MPTP-induced PD Sirtuin3 knock-out animals.
“EMPA treatment further reduced the oxidative stress and neurotoxicity through the modulation of glutathione (GSH) system and reduction of 3-hydroxykynurenine (3OHK) in Sirtuin3 knock-out (S3KO) animals.”
Animalsin MPTP-induced PD Sirtuin3 knock-out animalsstriatum
Research SquarePreprint
Empagliflozin decreases oxidative stress and ROS signaling in rats (doxorubicin-induced nephrotoxicity).
“EMPA mitigated oxidative stress in renal tissues, as presented by a reduction in malondialdehyde and an increase in both reduced glutathione and superoxide dismutase.”
Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales
The Journal of pharmacology and experimental therapeutics
Empagliflozin decreases oxidative stress and ROS signaling in HFD/STZ-treated diabetic rats.
“EMPA treatment decreased oxidative stress”
Animalsin HFD/STZ-treated diabetic ratsheart10 mg/kgeight weeksmales
Journal of food and drug analysis
Empagliflozin decreases oxidative stress and ROS signaling in rat renal ischemia-reperfusion model.
“Empagliflozin administration significantly reduced creatinine, urea, inflammatory markers, and oxidative stress levels.”
Animalsin rat renal ischemia-reperfusion modeln = 30
Advanced pharmaceutical bulletin
Empagliflozin decreases oxidative stress and ROS signaling in rats (doxorubicin-induced cognitive impairment model).
“attributed to its antioxidant and neuroplasticity-enhancing properties”
Animalsdoxorubicin-induced cognitive impairment modelbrain10 mg/kg, PO28 days
Molecular neurobiology
Empagliflozin decreases oxidative stress and ROS signaling in hHTG rats fed standard diet.
“along with reduction of markers of inflammation, oxidative stress and cell senescence”
Animalsin hHTG rats fed standard dietliver, adipose tissue and kidneysix weeksmales
International journal of molecular sciences
Empagliflozin decreases oxidative stress and ROS signaling in mice (high fructose diet-induced hyperglycemia).
“EMPA Nps significantly showed reduced levels of inflammatory mediators and oxidative stress.”
Animalshigh fructose diet-induced hyperglycemiananoparticles
Neurochemistry international
All 12Fewer
Apoptosis
downin cells2downin mice2downin rats2upin human cells1+1
8 studies
Apoptosis
downin cells2downin mice2downin rats2upin human cells1+1
Empagliflozin increases apoptosis in human cells (lung cancer).
“EMPA altered cell‐cycle progression and increased apoptotic cell death, accompanied by enhanced BAX and CASP3 expression and cleaved caspase‐3 activation.”
Cellslung cancerA549 and HOP-92 cells
Journal of biochemical and molecular toxicology
Empagliflozin decreases apoptosis in human cells.
“serum collected during empagliflozin treatment significantly reduced endothelial cell apoptosis, eEV release, VCAM-1 expression, and mitochondrial reactive oxygen species in vitro”
Cellsserum collected during treatment, in vitro model of human coronary artery endothelial cellscoronary artery endothelial cell10 mg daily
Arteriosclerosis, thrombosis, and vascular biology
Empagliflozin decreases apoptosis in mice (ATO-treated).
“reduces apoptosis.”
AnimalsATO-treated
Journal of toxicology
Empagliflozin decreases apoptosis in rats (doxorubicin-induced nephrotoxicity).
“Collectively, antioxidant, anti-inflammatory, and antiapoptotic influences contributed to the preservative potential of EMPA against DOX-induced kidney toxicity.”
Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales
The Journal of pharmacology and experimental therapeutics
Empagliflozin inhibits apoptosis in cells (high-glucose and high-uric acid conditions).
“decreased cleaved caspase-3 levels.”
Cellshigh-glucose and high-uric acid conditions
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
Empagliflozin decreases apoptosis in HFD/STZ-treated diabetic rats.
“EMPA treatment decreased cardiomyocyte apoptosis”
Animalsin HFD/STZ-treated diabetic ratsheart10 mg/kgeight weeksmales
Journal of food and drug analysis
Empagliflozin decreases apoptosis in diabetic nephropathy mice, bioinformatic analysis.
“This finding indicated that empagliflozin may inhibit the progression of diabetic nephropathy by inhibiting inflammation, apoptosis, and senescence.”
Animalsin diabetic nephropathy mice, bioinformatic analysis
Archivos espanoles de urologia
Empagliflozin decreases apoptosis in cells (ethanol-induced injury in H9c2 cells).
“EMPA pretreatment significantly reduced apoptosis of cardiomyocytes, and reduced the expression of cleaved caspase 3.”
Cellsethanol-induced injury in H9c2 cells
Clinical and experimental pharmacology & physiology
Autophagy
upin human cells2upin cells1upin mice1downin mice1+2
7 studies
Autophagy
upin human cells2upin cells1upin mice1downin mice1+2
Empagliflozin increases autophagy in human cells (lung cancer).
“EMPA increased LC3‐II without p62 accumulation, consistent with increased autophagic activity”
Cellslung cancerA549 and HOP-92 cells
Journal of biochemical and molecular toxicology
Empagliflozin increases autophagy in mouse cells.
“EMP enhanced autophagic activity and attenuated senescent phenotype in vitro.”
Cellschondrocyte
Biomedicines
Empagliflozin activates autophagy in cells (high-glucose and high-uric acid conditions).
“Empagliflozin treatment increased LC3 expression and AMPK phosphorylation”
Cellshigh-glucose and high-uric acid conditions
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
Empagliflozin increases autophagy in mice (co-treatment with ponatinib versus ponatinib alone).
“showed increased autophagy, decreased Cx43 expression as well as Cx43 lateralization”
Animalsco-treatment with ponatinib versus ponatinib aloneheart28 daysmales
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Empagliflozin activates autophagy in rotenone-exposed zebrafish.
“EMP treatment improved DOPAC/DA ratio, Y-Maze task, locomotor activity, expressions of Th and Lcp-1, autophagy and inflammation related (mTor, atg5, tnfα, sirt1, il6, tnfα)”
Animalsin rotenone-exposed zebrafishbrain30 days
Brain research
Empagliflozin inhibits autophagy in mice (streptozotocin-induced diabetes) (7.9 ± 0.05 vs. 2.3 ± 0.6 fluorescence intensity/total area).
“autophagy (7.9 ± 0.05 vs. 2.3 ± 0.6 fluorescence intensity/total area, P < 0.01)”
Animalsstreptozotocin-induced diabetesheart30 mg/kg/daymales
Cardiovascular research
Empagliflozin induces autophagy in human cells (7 ± 4.3 versus 2.6 ± 2.3 mean fluorescence with vehicle).
“and induced autophagy (E 500 7 ± 4.3 vs basal DMSO 2.6 ± 2.3 mean fluorescence vs PON 2.6 ± 2.4 mean fluorescence, p < 0.05)”
Cellshuman aortic endothelial cells500 nmol/L
Vascular pharmacology
Cardiac function
upin mice4upin rats2upin zebrafish1
7 studies
Cardiac function
upin mice4upin rats2upin zebrafish1
Empagliflozin improves cardiac function in zebrafish (Doxorubicin-treated AB zebrafish).
“Echocardiography showed DOX raised the E/A ratio and myocardial performance index at 28-42 dpi, which both agents attenuated (p<0.05).”
AnimalsDoxorubicin-treated AB zebrafishHeart6.2 mg/kg daily28–42 days post-injection
AHA Scientific Sessions 2026 abstract
Empagliflozin improves cardiac function in rats (aortic stenosis).
“Empagliflozin (10 mg/kg/day for 8 weeks) attenuated cardiac dysfunction and reduced HF features.”
Animalsaortic stenosisheart10 mg/kg/day8 weeks
Molecular biomedicine
Empagliflozin improves cardiac function in mice (myocardial infarction induced by permanent coronary artery ligation).
“Empagliflozin significantly improved cardiac remodeling and cardiac function in ischemic HF model”
Animalsmyocardial infarction induced by permanent coronary artery ligationheart10 mg/kg daily3 days before operation until 3 weeks after myocardial infarctionmales
ESC Congress 2026 abstract
Empagliflozin improves cardiac function in rats (ISO-induced myocardial injury).
“Compared with the model group, empagliflozin improved cardiac function”
AnimalsISO-induced myocardial injuryheart
Scientific reports
Empagliflozin improves cardiac function in mouse models of HF induced by transverse aortic constriction.
“Empagliflozin preserved cardiac function and markedly reduced myocardial fibrosis and HF markers.”
Animalsin mouse models of HF induced by transverse aortic constriction2 weeks
Journal of the American Heart Association
Empagliflozin improves cardiac function in mice (streptozotocin-induced diabetes).
“EMPA significantly reversed cardiac dysfunction on echocardiography in diabetic mice”
Animalsstreptozotocin-induced diabetesheart30 mg/kg/daymales
Cardiovascular research
Empagliflozin improves cardiac function in mice (streptozotocin-induced diabetes) (P < .01).
“Empagliflozin also reversed cardiac dysfunction, cardiac fibrosis and cell senescence in mice with (STZ)-induced diabetes (P < .01).”
Animalsstreptozotocin-induced diabetesheart
Journal of cellular and molecular medicine
HbA1c
downin humans6
6 studies
HbA1c
downin humans6
Empagliflozin decreases HbA1c in humans (Type 2 diabetes mellitus with heart failure; added to standard therapy) (9.02 ± 1.42% to 8.83 ± 1.11%).
“The HbA1c levels decreased from 9.02 ± 1.42% to 8.83 ± 1.11%, reflecting improved glycemic control following treatment.”
Human trialType 2 diabetes mellitus with heart failure; added to standard therapy10 to 25mg once a day12 weeksn = 20
ESC Congress 2026 abstract
Empagliflozin decreases HbA1c in humans (single-arm design, no control group) (9.17% ± 1.24% to 8.36% ± 1.01%).
“HbA1c (9.17% ± 1.24% to 8.36% ± 1.01%; p < 0.001)”
Human trialsingle-arm design, no control group10 mg once daily6 months44% malesn = 75
Echocardiography (Mount Kisco, N.Y.)
Empagliflozin decreases HbA1c in patients with diabetic osteoporosis.
“After six months of treatment, the intervention group exhibited significantly lower levels of FBG (P < 0.001), 2 h-PG (P = 0.001), and HbA1c (P < 0.001) than the control group.”
Human trialin patients with diabetic osteoporosis6 monthsn = 100
BMC musculoskeletal disorders
Empagliflozin decreases HbA1c in humans (placebo-adjusted) (-0.57% (95% CI -0.78, -0.36)).
“The placebo-adjusted mean change from baseline in HbA1c at week 52 with empagliflozin was -0.57% [95% confidence interval (CI) -0.78, -0.36].”
Human trialplacebo-adjusted10 mg once daily52 weeks
Diabetes, obesity & metabolism
Empagliflozin is linked with lower HbA1c in patients with type 2 diabetes.
“The empagliflozin group showed significant improvements in HbA1c, fasting plasma glucose, body weight, waist circumference, and fat mass (p < 0.05 for all).”
Humansin patients with type 2 diabetes6 months
Medicina (Kaunas, Lithuania)
Empagliflozin decreases HbA1c in humans (type 2 diabetes mellitus with established cardiovascular disease) (SMD -0.62, 95% CI -0.95 to -0.30).
“Our study concluded that empagliflozin significantly reduced HbA1c levels”
Reviewtype 2 diabetes mellitus with established cardiovascular disease
Annals of medicine and surgery (2012)
Body weight
downin humans5no changein mice1
6 studies
Body weight
downin humans5no changein mice1
Empagliflozin decreases body weight in humans (placebo-adjusted) (-2.37 kg (95% CI -3.07, -1.68)).
“Change in body weight was -3.26 kg and -0.90 kg with empagliflozin and placebo, respectively (placebo-adjusted difference: -2.37 kg; 95% CI -3.07, -1.68).”
Human trialplacebo-adjusted10 mg once daily52 weeks
Diabetes, obesity & metabolism
Empagliflozin is linked with lower body weight in kidney transplant recipients (2.4 kg average decrease).
“weight decreased on average 2.4 kg throughout the year”
Humansin kidney transplant recipientsthroughout the year
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
Transplantation proceedings
Empagliflozin is linked with lower body weight in humans (compared in non-elderly and elderly subjects).
“Although the body weight and HbA1c, AST, ALT and γ-GTP levels were significantly reduced in both the non-elderly and elderly subjects”
Humanscompared in non-elderly and elderly subjectssix monthsn = 110
Diabetes, metabolic syndrome and obesity : targets and therapy
Empagliflozin showed no clear effect on body weight in mice (doxorubicin-treated mice).
“EMPA neither attenuated nor exacerbated DOX-induced body weight, skeletal muscle, or WAT loss.”
Animalsdoxorubicin-treated mice10 mg/kg/day6 weeksmalesn = 36
Scientific reports
Empagliflozin decreases body weight in people without diabetes.
“In human investigations, EMPA significantly lowered body weight with notable improvements in fasting glucose.”
Reviewin people without diabetes10-12.5 mg daily
International journal of endocrinology
Empagliflozin decreases body weight in humans (type 2 diabetes mellitus with established cardiovascular disease) (SMD -2.32, 95% CI -3.42 to -1.21).
“Additionally, a reduction in body weight was also noted”
Reviewtype 2 diabetes mellitus with established cardiovascular disease
Annals of medicine and surgery (2012)
Adverse events
no changein humans4downin humans1
5 studies
Adverse events
no changein humans4downin humans1
Empagliflozin showed no clear effect on adverse events in humans (ADPKD at high risk of progression; not treated with tolvaptan; compared with placebo).
“Frequency of adverse events was similar between the 2 groups.”
Human trialADPKD at high risk of progression; not treated with tolvaptan; compared with placebo25 mg once daily12 monthsn = 50
Empagliflozin was well tolerated in a kidney disease trial
Journal of the American Society of Nephrology : JASN
Empagliflozin showed no clear effect on adverse events in humans.
“Adverse events were minimal and showed no significant differences between the two study arms (P > 0.05).”
Human trial6 months
Research SquarePreprint
Empagliflozin showed no clear effect on adverse events in humans after heart valve surgery; includes hypoglycemia and infection.
“No significant differences were observed in postoperative CRP levels (p = 0.12) or adverse event rates, including hypoglycemia and infection.”
Human trialafter heart valve surgery; includes hypoglycemia and infection10 mg daily3 days pre-op to 3 days post-opn = 81
Indian journal of thoracic and cardiovascular surgery
Empagliflozin decreases adverse events in hospitalized acute heart failure.
“Frequencies of adverse events were consistently lower with empagliflozin vs placebo.”
Human trialin hospitalized acute heart failure10 mg/dday 90
JACC. Heart failure
Empagliflozin was not clearly linked with adverse events in humans (added to standard medical therapy in heart failure after acute anterior STEMI).
“The incidence of adverse events was similar between groups”
Humansadded to standard medical therapy in heart failure after acute anterior STEMI10 mg once dailyn = 98
Reviews in cardiovascular medicine
Quality of life
upin humans4no changein humans1
5 studies
Quality of life
upin humans4no changein humans1
Empagliflozin showed no clear effect on quality of life in humans (placebo-controlled comparison; exploratory outcome).
“No significant treatment differences were observed for neither daily physical activity nor QoL.”
Human trialplacebo-controlled comparison; exploratory outcome180 days
American heart journal
Empagliflozin improves quality of life in humans (chronic syndrome of inappropriate antidiuresis following traumatic subarachnoid hemorrhage).
“This allowed increased fluid intake (1750 mL/day) and improved quality of life.”
Human trialchronic syndrome of inappropriate antidiuresis following traumatic subarachnoid hemorrhage25 milligrams/day16 monthsfemales
JCEM case reports
Empagliflozin is linked with better quality of life in patients with stable heart failure.
“The GNRI, MNA, KCCQ-12, body mass index, and NT-proBNP levels improved significantly”
Humansin patients with stable heart failure10 mg daily6 monthsn = 93
BMC cardiovascular disorders
Empagliflozin is linked with better quality of life in humans (heart failure) (74.3 ± 19.5 vs. 67.1 ± 19.5, p<0.01).
“A significant improvement was observed in the KCCQ-12 overall score (74.3 ± 19.5 vs. 67.1 ± 19.5, p<0.01)”
Humansheart failure24 weeksn = 101
Orvosi hetilap
Empagliflozin improves quality of life in humans.
“improved quality of life measures”
Review
Cureus
Cognitive function
upin humans2upin rats2upin mice1
5 studies
Cognitive function
upin humans2upin rats2upin mice1
Empagliflozin improves cognitive function in humans (frail older adults with type 2 diabetes and HFpEF) (Montreal Cognitive Assessment 19.80 to 22.25 after 1 month (P < 0.001)).
“Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group”
Human trialfrail older adults with type 2 diabetes and HFpEF1 month
Diabetes care
Empagliflozin is linked with better cognitive function in humans.
“At 3-month follow-up, we detected a significant improvement in the MoCA score and in the 5mGS in patients receiving empagliflozin compared with non-treated subjects.”
Humansfrail older adults with diabetes and hypertension, propensity-matched against non-treated patients3 months
Hypertension (Dallas, Tex. : 1979)
Empagliflozin improves cognitive function in rats (AlCl3-induced AD) (4.17-fold).
“improved locomotor activity (1.86-fold) and cognitive performance (T-maze) (4.17-fold).”
AnimalsAlCl3-induced AD
Pharmaceutics
Empagliflozin improves cognitive function in streptozotocin-induced diabetic rats.
“empagliflozin reversed these changes, improving SOD and CAT activity, GLT content and reducing Nox-4 expression and MDA concentration in brain tissue while improving cognitive ability”
Animalsin streptozotocin-induced diabetic ratsbrain20 mg/kg oral5 weeksmalesn = 8
Behavioural brain research
Empagliflozin improves cognitive function in high-fat diet plus streptozotocin T2D-AD mice.
“SGLT2-i and DPP4-i significantly improved hippocampal-dependent learning, memory, and cognitive functions in the T2D-AD mouse model.”
Animalsin high-fat diet plus streptozotocin T2D-AD mice25 mg/kg/day7 weeks
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
NT-proBNP
downin humans3upin humans1
4 studies
NT-proBNP
downin humans3upin humans1
Empagliflozin decreases NT-proBNP in humans (Heart failure with reduced ejection fraction and type 2 diabetes or prediabetes).
“Across the overall study population, uric acid and NT-proBNP decreased and haematocrit increased”
Human trialHeart failure with reduced ejection fraction and type 2 diabetes or prediabetes36 weeksn = 105
Empagliflozin reduced heart chamber volumes alongside other drugs
ESC Congress 2026 abstract
Empagliflozin decreases NT-proBNP in humans.
“Notably, there were significant improvements in GNRI (p < 0.001), MNA (p < 0.001), KCCQ12-OS (p < 0.01), KCCQ12-CS (p < 0.01), BMI (p = 0.005), and NT-proBNP (p < 0.001).”
Human trial6 monthsn = 93
BMC cardiovascular disorders
Empagliflozin is linked with better NT-proBNP in humans (heart failure, with or without diabetes).
“and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (p < 0.001).”
Humansheart failure, with or without diabetes10 mg dailysix monthsn = 797
BMC endocrine disorders
Empagliflozin is linked with lower NT-proBNP in humans (type 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulin) (1699 ± 522 vs. 2303 ± 598 pg/ml at discharge).
“the N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were lower in the empagliflozin continuation group than in the insulin group”
Humanstype 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulincombined with basal insulin regimenduring hospitalization
Journal of the American Geriatrics Society
Left ventricular ejection fraction
upin humans2no changein humans1upin mice1
4 studies
Left ventricular ejection fraction
upin humans2no changein humans1upin mice1
Empagliflozin showed no clear effect on left ventricular ejection fraction in humans (Type 2 diabetes mellitus with heart failure; added to standard therapy).
“The left ventricular ejection fraction remained relatively stable, with no significant change (p > 0.05).”
Human trialType 2 diabetes mellitus with heart failure; added to standard therapyheart10 to 25mg once a day12 weeksn = 20
ESC Congress 2026 abstract
Empagliflozin is linked with higher left ventricular ejection fraction in humans (1.92% (95% CI 0.44-3.40%; p = 0.012)).
“the SGLT2i group showed a significantly greater improvement in LVEF than the control group”
Humansadded to standard medical therapy in heart failure after acute anterior STEMI; multivariable-adjustedleft ventricle10 mg once dailyadmission to one month after dischargen = 98
Reviews in cardiovascular medicine
Empagliflozin is linked with better left ventricular ejection fraction in humans (heart failure, with or without diabetes).
“echocardiographic parameters such as left ventricular ejection fraction (LVEF) (p = 0.003)”
Humansheart failure, with or without diabetesheart10 mg dailysix monthsn = 797
BMC endocrine disorders
Empagliflozin increases left ventricular ejection fraction in mice (Males +9±3%; females +10±2%; both p<0.0001).
“improved LVEF by 9±3% and 10±2%, respectively (both p<0.0001).”
AnimalsEstablished pressure-overload left ventricular hypertrophy after transverse aortic constrictionheart30 mg/kg/dayfour weeks
ESC Congress 2026 abstract
Systolic blood pressure
downin humans3downin rats1
4 studies
Systolic blood pressure
downin humans3downin rats1
Empagliflozin decreases systolic blood pressure in humans.
“greater reductions in systolic blood pressure were observed with empagliflozin and combination therapy versus finerenone alone at higher baseline BMI”
Human trialChronic kidney disease and type 2 diabetes; higher baseline BMI; compared with finerenone alone
ESC Congress 2026 abstract
Empagliflozin decreases systolic blood pressure in humans (-8.14 mmHg).
“At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was -8.14 mmHg (95% CI − 10.32, − 3.96, P = 0.005).”
Human trial12 weeksn = 124
Scientific reports
Empagliflozin decreases systolic blood pressure in hypertensive patients with diabetes (SBP -5.93 mm Hg).
“largest numerical effect for empagliflozin 25 mg (SBP -5.93 mm Hg)”
Reviewin hypertensive patients with diabetes25 mg
International journal of cardiology. Cardiovascular risk and prevention
Empagliflozin decreases systolic blood pressure in rats (obese ZSF1 rats).
“These effects were prevented by the empa treatment.”
Animalsobese ZSF1 rats30 mg/kg/day6 weeks
Cardiovascular diabetology
Frailty
no changein humans2downin humans1
3 studies
Frailty
no changein humans2downin humans1
Empagliflozin showed no clear effect on frailty in humans.
“In contrast, there was no significant change in the CONUT score, Barthel index, or clinical frailty score.”
Human trial6 monthsn = 93
BMC cardiovascular disorders
Empagliflozin decreases frailty in humans (at Week 12) (odds ratio: 1.12 [95% confidence interval, CI, 1.01–1.24]).
“Compared with placebo, empagliflozin patients had a higher likelihood of being in a lower FI category at Weeks 12, 32 and 52, odds ratio: 1.12 [95% confidence interval, CI, 1.01–1.24], 1.21 [1.09–1.34] and 1.20 [1.09–1.33] at Week 12, 32 and 52; P = 0.030, <0.001 and <0.001, respectively.”
Human trialat Week 12median of 26 monthsn = 5,988
Journal of cachexia, sarcopenia and muscle
Empagliflozin was not clearly linked with frailty in patients with stable heart failure.
“whereas the CONUT, Barthel index, and frailty scores remained unchanged”
Humansin patients with stable heart failure10 mg daily6 monthsn = 93
BMC cardiovascular disorders
Empagliflozin was not clearly linked with frailty in humans (over approximately six months, in older adults with type 2 diabetes).
“Neither drug negatively affected frailty, cognition, physical performance, or sleep.”
Humansover approximately six months, in older adults with type 2 diabetesapproximately six monthsn = 20
Endocrine
All 451Fewer
What is empagliflozin linked with?
80Studies link empagliflozin with 80 measures, most often mortality (6 studies), major adverse cardiovascular events (4) and dementia (3).
Mortality
downin humans6RR 0.73
6 studies
Mortality
downin humans6RR 0.73
Empagliflozin lowers the risk of mortality in humans (compared with placebo, network meta-analysis) (OR 0.69 (95% CI 0.62-0.76)).
“sotagliflozin (OR 0.50; 95% CI: 0.40-0.63;p-score=0.98), empagliflozin (OR 0.69; 95% CI 0.62-0.76; p-score=0.88), and metformin (OR 0.79; 95% CI 0.35-1.75; p-score=0.63) had lowest odds of mortality”
Human trialcompared with placebo, network meta-analysis
ADA Scientific Sessions 2026 abstract
Empagliflozin is linked with a lower risk of mortality in humans (early initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation) (RR 0.73, 95% CI 0.69-0.78; 1-year absolute mortality 24.7% early vs 33.6% delayed or no initiation).
“early and intermediate empagliflozin initiation were associated with lower 1-year post-discharge all-cause mortality than delayed or no initiation (risk ratio [RR] 0.73, 95% confidence interval [CI]: 0.69-0.78”
Humansearly initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation1 year post-dischargen = 99,738
ESC heart failure
Empagliflozin is linked with a lower risk of mortality in humans (compared with DPP4 inhibitors) (HR 0.66 [0.57, 0.76]; IRD -8.6 (-11.4, -5.8)).
“ACM (HR 0.66 [0.57, 0.76]; IRD = -8.6 [-11.4, -5.8])”
Humanscompared with DPP4 inhibitors
Diabetes care
Empagliflozin is linked with a lower risk of mortality in humans (type 2 diabetes) (adjusted HR 0.76, 95% CI 0.69 to 0.83).
“all-cause mortality occurred in 551 out of 13,239 (4.2%) in the empagliflozin group and 6,589 out of 49,264 (13.4%) in the active control group (adjusted HR 0.76, 95% CI 0.69 to 0.83)”
Humanstype 2 diabetesn = 49,264
BMJ open diabetes research & care
Empagliflozin is linked with a lower risk of mortality in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.75, 95% CI 0.59-0.96).
“empagliflozin was associated with lower all-cause mortality (HR 0.75, 95% CI 0.59-0.96)”
Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year
medRxiv : the preprint server for health sciencesPreprint
Empagliflozin is linked with a lower risk of mortality in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.66 (0.60, 0.72); RD= -8.48 (-10.14, -6.82)).
“and mortality [HR=0.66 (0.60, 0.72); RD= -8.48 (-10.14, -6.82)] vs DPP4i”
Humansvs DPP4i, propensity-matched Medicare cohort
ADA Scientific Sessions 2025 abstract
Major adverse cardiovascular events
downin humans4HR 0.68–0.77
4 studies
Major adverse cardiovascular events
downin humans4HR 0.68–0.77
Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with DPP4 inhibitors) (HR 0.77, 99.9% CI 0.69–0.85; IRD -10.3 (-14.1, -6.4)).
“Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]”
Humanscompared with DPP4 inhibitors
Diabetes care
Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.77 (0.72, 0.81); RD= -10.10 (-12.38, -7.83)).
“EMPA was associated with decreased risk of MACE [HR=0.77 (0.72, 0.81); RD= -10.10 (-12.38, -7.83)]”
Humansvs DPP4i, propensity-matched Medicare cohort
ADA Scientific Sessions 2025 abstract
Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with DPP-4i) (HR 0.73 [0.62, 0.86]; RD -6.37 per 1000 person-years).
“MACE (HR 0.73 [0.62, 0.86]; RD -6.37 [-8.98, -3.77])”
Humanscompared with DPP-4in = 115,116
Effectiveness and safety of empagliflozin: final results from the EMPRISE study
Diabetologia
Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (relative to sitagliptin, Medicare beneficiaries with type 2 diabetes) (HR 0.68 (95% CI 0.60-0.77)).
“Compared with sitagliptin, empagliflozin was associated with reduced risks of the modified MACE outcome (HR, 0.68; 95% CI, 0.60-0.77)”
Humansrelative to sitagliptin, Medicare beneficiaries with type 2 diabetesn = 45,624
JAMA network open
Dementia
downin humans3HR 0.59–0.69
3 studies
Dementia
downin humans3HR 0.59–0.69
Empagliflozin is linked with a lower risk of dementia in humans (propensity score-matched cohort of older adults with heart failure, EHR data) (HR 0.59, 95% CI 0.52–0.67).
“Empagliflozin use was associated with significantly reduced risk of AD (HR 0.61, 95% CI 0.48–0.77, p<0.001), VD (HR 0.56, 95% CI 0.44–0.71, p<0.001), unspecified dementia (HR 0.59, 95% CI 0.52–0.67, p<0.001)”
Humanspropensity score-matched cohort of older adults with heart failure, EHR data2-year follow-upn = 32,761
AHA Scientific Sessions 2025 abstract
Empagliflozin is linked with a lower risk of dementia in humans (compared with DPP-4 inhibitors) (aHR 0.78 (95% CI 0.69-0.89)).
“followed by empagliflozin (aHR 0.78 [95% CI 0.69-0.89])”
Humanscompared with DPP-4 inhibitorsmean follow-up 2.80 years
Diabetes care
Empagliflozin lowers the risk of dementia in humans (network meta-analysis versus other antidiabetic medications or placebo) (HR 0.69, 95% CrI 0.55–0.85; highest probability of being ranked most effective (81.2%)).
“and Empagliflozin (HR = 0.69, 95% CrI: 0.55, 0.85) significantly reduced the risk of dementia onset.”
Reviewnetwork meta-analysis versus other antidiabetic medications or placebo
Frontiers in endocrinology
Hospitalization for heart failure
downin humans2RR 0.54–0.75
2 studies
Hospitalization for heart failure
downin humans2RR 0.54–0.75
Empagliflozin lowers the risk of hospitalization for heart failure in humans (Prediabetes and heart failure; compared with placebo) (RR 0.75, 95% CI 0.60–0.93, p = 0.010).
“empagliflozin (RR 0.75, 95% CI 0.60–0.93, p = 0.010) in patients with prediabetes and heart failure.”
ReviewPrediabetes and heart failure; compared with placebo
Medical sciences (Basel, Switzerland)
Empagliflozin lowers the risk of hospitalization for heart failure in humans (Heart failure with mildly reduced or preserved ejection fraction; compared with exenatide) (RR 0.54, 95% CI 0.34-0.86).
“empagliflozin (RR 0.54, 95% CI 0.34-0.86), and semaglutide (RR 0.43, 95% CI 0.20-0.91) were related to decreased risk of HF hospitalization.”
ReviewHeart failure with mildly reduced or preserved ejection fraction; compared with exenatide
Drugs
Major adverse cardiovascular events
upin humans1downin humans1RR 1.55
2 studies
Major adverse cardiovascular events
upin humans1downin humans1RR 1.55
Empagliflozin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with dapagliflozin) (RR 1.55, 95% CI 0.93–2.59; P = 0.094).
“empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93–2.59; P = 0.094)”
HumansACS and multivessel coronary disease; compared with dapagliflozin3 monthsn = 277
PloS one
Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with GLP-1RA after propensity score matching) (HR 0.90 (0.82, 0.99); RD -2.54 (-4.76, -0.32) per 1,000 person-years).
“MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)]”
Humanscompared with GLP-1RA after propensity score matchingn = 141,541
Cardiovascular diabetology
Emphysematous cystitis
upin humans2
2 studies
Emphysematous cystitis
upin humans2
Empagliflozin is associated with emphysematous cystitis in a patient with type 2 diabetes.
“We present a unique case of this gas-forming infection in a man with type 2 diabetes mellitus (T2DM) treated with empagliflozin.”
Humansin a patient with type 2 diabetesurinary bladderfour months after initiationmalesn = 1
AACE clinical case reports
Empagliflozin is associated with emphysematous cystitis in humans (published case reports; causality remains uncertain).
“Empagliflozin-associated emphysematous cystitis is a rare but serious condition mostly seen in elderly patients with multiple health issues and urinary tract abnormalities.”
Reviewpublished case reports; causality remains uncertainurinary bladdern = 7
Empagliflozin-associated emphysematous cystitis: a systematic review of published case reports
Review of Clinical Pharmacology and Pharmacokinetics - International Edition
All-cause hospitalization
downin humans2RR 0.91
2 studies
All-cause hospitalization
downin humans2RR 0.91
Empagliflozin lowers the risk of all-cause hospitalization in patients with CKD (HR 0.86 (95% CI 0.78 to 0.95); 14% relative risk reduction).
“and all-cause hospitalization by 14% (hazard ratio, 0.86; 95% confidence interval, 0.78 to 0.95)”
Human trialin patients with CKD10 mg daily2 years (median)n = 6,609
Clinical journal of the American Society of Nephrology : CJASN
Empagliflozin is linked with a lower risk of all-cause hospitalization in humans (early initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation) (RR 0.91, 95% CI 0.88-0.94).
“and all-cause hospitalisations (RR 0.91, 95% CI: 0.88-0.94)”
Humansearly initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation1 year post-dischargen = 99,738
ESC heart failure
Heart failure
downin humans2HR 0.64–0.72
2 studies
Heart failure
downin humans2HR 0.64–0.72
Empagliflozin is linked with a lower risk of heart failure in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.64, 95% CI 0.57-0.73).
“and HF exacerbations (HR 0.64, 95% CI 0.57-0.73) compared to dapagliflozin”
Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year
medRxiv : the preprint server for health sciencesPreprint
Empagliflozin is linked with a lower risk of heart failure in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.72 (0.69, 0.76); RD= -17.68 (-20.45, -14.91)).
“HHF [HR=0.72 (0.69, 0.76); RD= -17.68 (-20.45, -14.91)]”
Humansvs DPP4i, propensity-matched Medicare cohort
ADA Scientific Sessions 2025 abstract
Hospitalization
downin humans2HR 0.61–0.86
2 studies
Hospitalization
downin humans2HR 0.61–0.86
Empagliflozin lowers the risk of hospitalization in humans (HR, 0.86; 95% CI, 0.78 to 0.95).
“Overall, there was a 14% reduction in total all-cause hospitalizations in participants allocated to empagliflozin versus placebo (HR, 0.86; 95% CI, 0.78 to 0.95), which was not clearly driven by a single cause of hospitalization (see previous reports).”
Human trialmedian 2.0 yearsn = 6,609
Clinical journal of the American Society of Nephrology : CJASN
Empagliflozin is linked with a lower risk of hospitalization in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.61, 95% CI 0.55-0.67).
“substantially fewer hospitalizations (HR 0.61, 95% CI 0.55-0.67)”
Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year
medRxiv : the preprint server for health sciencesPreprint
Estimated glomerular filtration rate
upin humans1no changein humans1
2 studies
Estimated glomerular filtration rate
upin humans1no changein humans1
Empagliflozin is associated with estimated glomerular filtration rate in humans (type 2 diabetes and stage 3 chronic kidney disease) (+2.75 mL/min/1.73m2 at 6 months).
“Overall, eGFR increased by 2.75 mL/min/1.73m2 at 6 months (p < 0.0001)”
Humanstype 2 diabetes and stage 3 chronic kidney disease6 monthsn = 166
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia
Empagliflozin is associated with estimated glomerular filtration rate in humans after rechallenge in CKD stage 4 (22–25 mL/min/1.73m2 over 12 months).
“Over 12 months, eGFR remained stable (22–25), and there were no further DKA episodes.”
Humansafter rechallenge in CKD stage 4kidney10 mg/dayover 12 monthsfemalesn = 1
AHA Scientific Sessions 2025 abstract
Cardiovascular death or HF hospitalization
downin humans2
2 studies
Cardiovascular death or HF hospitalization
downin humans2
Empagliflozin lowers the risk of cardiovascular death or HF hospitalization in humans (irrespective of baseline IGFBP7 tertile).
“Empagliflozin reduced risk for cardiovascular death/HF hospitalization irrespective of baseline IGFBP7”
Human trialirrespective of baseline IGFBP7 tertile
European journal of heart failure
Empagliflozin lowers the risk of cardiovascular death or HF hospitalization in humans.
“Empagliflozin also reduced the primary endpoint compared with placebo across the spectrum of patient age taken as a continuous variable (p for interaction = 0.24; online supplementary Figure ).”
Human trial52 weeksn = 3,730
European journal of heart failure
Kidney disease progression or cardiovascular death
downin humans1HR 0.72
1 study
Kidney disease progression or cardiovascular death
downin humans1HR 0.72
Empagliflozin lowers the risk of kidney disease progression or cardiovascular death in patients with CKD (HR 0.72 (95% CI 0.64 to 0.82); 28% relative risk reduction).
“allocation to empagliflozin reduced the risk of the primary outcome of kidney disease progression or cardiovascular death by 28% (hazard ratio, 0.72; 95% confidence interval, 0.64 to 0.82)”
Human trialin patients with CKD10 mg daily2 years (median)n = 6,609
Clinical journal of the American Society of Nephrology : CJASN
Empagliflozin lowers the risk of kidney disease progression or cardiovascular death in humans (HR, 0.72; 95% CI, 0.64 to 0.82).
“Overall, versus placebo, empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death by 28% (HR, 0.72; 95% CI, 0.64 to 0.82”
Human trialmedian 2.0 yearsn = 6,609
Clinical journal of the American Society of Nephrology : CJASN
Cardiovascular death or heart failure hospitalization
downin humans1HR 0.59
1 study
Cardiovascular death or heart failure hospitalization
downin humans1HR 0.59
Empagliflozin lowers the risk of cardiovascular death or heart failure hospitalization in humans (HR for non-frail group shown; severe frailty HR 0.90 (0.69-1.16) not significant) (HR 0.59 (95% CI 0.42-0.83) in non-frail; 0.90 (0.69-1.16) in severe frailty).
“Compared with placebo, empagliflozin reduced the risk for the primary outcome across the four FI categories”
Human trialHR for non-frail group shown; severe frailty HR 0.90 (0.69-1.16) not significant
Journal of cachexia, sarcopenia and muscle
Empagliflozin lowers the risk of cardiovascular death or heart failure hospitalization in humans (non-frail group) (HR 0.59 (0.42, 0.83)).
“Major adverse clinical outcomes of the EMPEROR‐Preserved trial were more likely in more severely frail patients, and the hazard ratio of primary outcome (time to first event of CV death or HHF) by empagliflozin treatment was 0.59 (0.42, 0.83), 0.79 (0.61, 1.01), 0.77 (0.61, 0.96) and 0.90 (0.69, 1.16) in the non‐frail, mild frailty, moderate frailty and severe frailty groups, respectively (P trend = 0.097”
Human trialnon-frail groupmedian of 26 monthsn = 1,514
Journal of cachexia, sarcopenia and muscle
Serum electrolytes
mixedin humans1
1 study
Serum electrolytes
mixedin humans1
Empagliflozin is associated with serum electrolytes in humans (Ambulatory heart failure; compared with placebo) (Sodium and chloride each +0.1 mmol/L; bicarbonate −0.2 mmol/L on average).
“empagliflozin slightly increased Na+ and Cl− by + 0.1 mmol/L on average, particularly from week 32 onwards (P < 0.05), while reducing serum bicarbonate levels”
Human trialAmbulatory heart failure; compared with placebo
Lower blood chloride linked to worse heart failure outcomes
Clinical research in cardiology : official journal of the German Cardiac Society
Liver stiffness
downin humans1
1 study
Liver stiffness
downin humans1
Empagliflozin is associated with liver stiffness in humans (T2DM and MASLD; single-arm pre–post comparison) (LSM: 7.22 ± 1.04 to 6.24 ± 0.41).
“12 weeks of empagliflozin treatment was associated with significant reductions in liver enzyme levels, hepatic steatosis, and liver stiffness”
Human trialT2DM and MASLD; single-arm pre–post comparisonliver25 mg/day12 weeksn = 30
Journal of diabetes investigation
All 80Fewer
Has empagliflozin been tested in people?
80 of 298 about agingYes: 94 trials and 117 observational studies in people have been published, and 281 trials are registered.
About aging
ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging
Phase 2Completed
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Phase 2Recruiting
Phase 4Completed
Phase 3Completed
Phase 3Completed
Phase 3Completed
All 40Fewer
Approved
May 22, 2014Diabetes Mellitus, Type 2, Heart Failure, Renal Insufficiency, Chronic, Chronic Heart Failure, Chronic Kidney Disease
Aug 1, 2014Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Disease, End Stage Kidney Disease, established cardiovascular disease
Repurposing
Phase 4Results posted6 trials
Phase 4Results posted6 trials
Phase 4Completed6 trials
Phase 4Completed1 trial
Phase 4Results posted25 trials
Phase 4Completed2 trials
40 of 96Fewer
Every condition in trials
Autosomal dominant polycystic kidney
Phase 4Active, not recruiting3 trials
Motor Activity
Phase 4Completed2 trials
TYPE2 diabetes
Phase 4Status unknown2 trials
Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans
Phase 3Status unknown2 trials
Lipoatrophic diabetes mellitus
Phase 3Status unknown2 trials
Type2 diabetes mellitus
Phase 3Completed2 trials
All 12Fewer
Readouts due
- Dec 11, 2026
- Dec 30, 2026
Safety and Efficacy of Empagliflozin in Hemodialysis
Phase 2Active, not recruiting
- Dec 31, 2026
- Mar 31, 2027
Feasibility Trial for a Right Ventricular Failure Platform Trial
Phase 2Recruiting
- Mar 31, 2027
Glycemic Variability of Combination Therapies in T2DM
Phase 4Recruiting
- Apr 16, 2027
All 11Fewer
Stopped
NCT02728453TerminatedType 2 diabetes
Insufficient recruitment.
NCT02985242TerminatedType 2 diabetes
difficulties to recruit planned numbers of patients within reasonable time frame
NCT05129722TerminatedHeart failure with preserved ejection fraction
Difficulties in recruitment at both sites.
NCT06844669TerminatedBreast neoplasm
Futility
NCT06818305TerminatedKidney neoplasm
The patient enrollment rate is proceeding too slowly
NCT05282121TerminatedPortal hypertension
Company decision
Who is developing empagliflozin?
3 companies: Boehringer Ingelheim, Nabiqasim Industries (Pvt) and Chong Kun Dang Pharmaceutical.
Trial sponsors
Company51 trialsPhase 432,016 people
Company4 trialsPhase 4286 people
Company3 trialsPhase 42,364 people
Company1 trialPhase 4800 people
Company1 trialPhase 4178 people
Profil Institut für Stoffwechselforschung
Company1 trialPhase 475 people
Company2 trialsPhase 316 people
Company1 trialPhase 3270 people
Funding
19 grants since 2017National Institute of Diabetes and Digestive and Kidney Diseases$2.9MNational Heart, Lung, and Blood Institute$3.5MSwiss National Science FoundationCHF 1.2M
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
National Heart, Lung, and Blood InstituteCleveland Clinic Lerner Com-cwru$815K2024–2030
EMbArK: Empagliflozin Treatment of Ischemic with Non-Obstructive Coronary Arteries (INOCA)
National Heart, Lung, and Blood InstituteUniversity of Cincinnati$734K2026–2031
An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)
US Department of Veterans AffairsOmaha Va Medical Center2024–2029
National Institute of Diabetes and Digestive and Kidney DiseasesMayo Clinic Rochester$318K2024–2027
Effects of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
National Heart, Lung, and Blood InstituteUniversity of Minnesota$202K2024–2029
Safety and Efficacy of Empagliflozin Main intenance HD (SEED)
National Institute of Diabetes and Digestive and Kidney DiseasesNew York University School of Medicine$342K2023–2027
Metabolomics of Empagliflozin after acute MI
FWF Austrian Science FundMedizinische Universitat Graz€380K2025–2027
Wellcome TrustThe Chancellor Masters and Scholars of the University of Cambridge2023–2026
Gouvernement du Canada | Canadian Institutes of Health ResearchUniversity of ManitobaCA$27K2024–2025
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
National Heart, Lung, and Blood InstituteCleveland Clinic Lerner Com-cwru$433K2024–2025
How this record changed
Summary rewritten as its findings changed.
As it read before
Empagliflozin reduces cardiovascular and kidney events in human trials; frailty improves in one trial but shows no clear change in another. Independent labs find reduced senescence in cells, while mouse results include increases. Developers sponsor 92 trials across uses; 75 registered trials concern aging, while 71 across uses ended over a year ago without posted results or citing papers.
Summary rewritten as its findings changed.
As it read before
Human trials report reduced frailty or no clear effect with empagliflozin; a trial reports reduced kidney disease progression or cardiovascular death. Independent labs report reduced senescence in cells, while mouse senescence results point both ways. Of registered trials, 76 concern aging; 71 across all uses ended over a year ago without posted results, and 93 of 297 have developer sponsorship.
Summary rewritten as its findings changed.
As it read before
Independent cell studies report reduced cellular senescence with empagliflozin; a human trial reports less kidney disease progression or cardiovascular death, while human trials disagree on frailty. It has 42 aging-related trials; across all uses, 73 trials ended over a year ago without posted results or citing papers. Its developers sponsor 87 trials across uses.
Summary rewritten as its findings changed.
As it read before
Independent labs report reduced cellular senescence with empagliflozin in cells; a human trial reports lower risk of kidney disease progression or cardiovascular death, while frailty results differ across human trials. Forty registered trials concern aging; 73 across uses ended over a year ago without posted results. Developer companies sponsor trials; Boehringer Ingelheim funds papers.
Summary rewritten as its findings changed.
As it read before
Empagliflozin reduces senescence in cells across independent labs and in mice; a human trial reports less kidney disease progression or cardiovascular death, while frailty results differ. Of its registered trials, 36 concern aging; 73 across all uses ended over a year ago without posted results or citing papers. Boehringer Ingelheim funds some papers, and developers sponsor 87 of 288 trials.